Bayer Animal Health GmbH and NeuroCycle Therapeutics, Inc. (NCT) have signed a global license agreement to advance innovative allergy treatment options for companion animals.
MONHEIM, 12 September 12, 2018: Bayer Animal Health GmbH and NeuroCycle Therapeutics, Inc. (NCT) have signed a global license agreement to advance innovative allergy treatment options for companion animals. As part of the license agreement, Bayer will develop and commercialize novel compounds based on knowledge and intellectual property licensed and controlled by NCT. Further terms of the agreement have not been disclosed.
Pet ownership is growing around the world and with that customers’ requirement for more effective and convenient treatment options. “At Bayer, we are committed to help pet owners improve the health and well-being of their animals,” said Dr. Sabine Bongaerts, Head of Development within Bayer Animal Health. “We know that allergies are among the most important health and well-being concerns for pet owners and veterinarians. The license agreement with NCT is a strong signal of our commitment to our customers around the world to address these concerns.”
Dr. Douglas Hutchens, Bayer Animal Health’s Head of Drug Discovery, External Innovation & Chief Veterinary Officer, added: “Today’s agreement underlines our strategy to combine the know-how from creative start-up companies like NCT with opportunities derived from Bayer’s research. It is a major milestone on our way to complementing our portfolio with novel treatment options against allergic diseases for the companion animal sector. Now, we will focus on evolving these options from research and development to market maturity.”
Dr. Jed Hubbs, NeuroCycle Therapeutics’ CEO added: “Our goal is to maximize the humanitarian impact of our innovative technologies. This license agreement with Bayer Animal Health aligns with this goal by allowing our technology to be applied beyond our core focus on human health.”